

Descovy - (200mg/ 25mg; Tablet)

Generic Name	Emtricitabine and Tenofovir Alafenamide Fumarate	Innovator	Gilead
Dosage	200mg/ 25mg; Tablet	Branded US Sales	More Than \$1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Descovy - (120mg/ 15mg; Tablet)

Generic Name	Emtricitabine and Tenofovir Alafenamide Fumarate	Innovator	Gilead
Dosage	120mg/ 15mg; Tablet	Branded US Sales	More Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.